Asia Deal Watch: Boost For Esperion's Cholesterol Candidate As Daiichi Brought On Board
Executive Summary
Daiichi Sankyo pays $150m upfront to commercialize Esperion's cholesterol drug and combination in Europe, while Gilead enters major deal worth up to $785m with Korea's Yuhan to bolster its NASH portfolio. Samsung taps 3SBio to build its biosimilars business in China.
You may also be interested in...
Asia Deal Watch: CANbridge Licenses Orphan Disease Candidates From Mirum, LogicBio
US-based, China-focused CANbridge moves into cholestatic liver disease and enzyme replacement therapy via two deals. Plus deals involving LegoChem, TransThera, Morepen, Daiichi Sankyo, Geneseeq, Innocare, Biosplice, Sirnaomics and Walvax.
Coronavirus Update: Trump Tests Positive, US Pause Remains On AstraZeneca Vaccine
Meanwhile, seven former US FDA commissioners issue joint plea for trust in the scientific integrity of the agency.
Corbus Seeking Way Forward In Systemic Sclerosis After Phase III
The company explained that background immunosuppressant therapy performed better than anticipated based on scientific literature and physicians’ expectations.